IL207530A - Triazolyl-phenyl compounds and their use in the manufacture of a cancer treatment drug - Google Patents

Triazolyl-phenyl compounds and their use in the manufacture of a cancer treatment drug

Info

Publication number
IL207530A
IL207530A IL207530A IL20753010A IL207530A IL 207530 A IL207530 A IL 207530A IL 207530 A IL207530 A IL 207530A IL 20753010 A IL20753010 A IL 20753010A IL 207530 A IL207530 A IL 207530A
Authority
IL
Israel
Prior art keywords
substituted
group
triazolyl
nitrogen
moiety
Prior art date
Application number
IL207530A
Other languages
English (en)
Hebrew (he)
Other versions
IL207530A0 (en
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40601237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL207530(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IL207530A0 publication Critical patent/IL207530A0/en
Publication of IL207530A publication Critical patent/IL207530A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL207530A 2008-02-21 2010-08-10 Triazolyl-phenyl compounds and their use in the manufacture of a cancer treatment drug IL207530A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3040708P 2008-02-21 2008-02-21
PCT/US2009/034447 WO2009105500A1 (en) 2008-02-21 2009-02-19 Compounds that are erk inhibitors

Publications (2)

Publication Number Publication Date
IL207530A0 IL207530A0 (en) 2010-12-30
IL207530A true IL207530A (en) 2014-08-31

Family

ID=40601237

Family Applications (1)

Application Number Title Priority Date Filing Date
IL207530A IL207530A (en) 2008-02-21 2010-08-10 Triazolyl-phenyl compounds and their use in the manufacture of a cancer treatment drug

Country Status (23)

Country Link
US (1) US8716483B2 (en:Method)
EP (1) EP2260031B1 (en:Method)
JP (1) JP5276676B2 (en:Method)
KR (1) KR20100117123A (en:Method)
CN (1) CN102015693B (en:Method)
AR (1) AR070460A1 (en:Method)
AU (1) AU2009215534B8 (en:Method)
BR (1) BRPI0908120A8 (en:Method)
CA (1) CA2714479A1 (en:Method)
CL (1) CL2009000394A1 (en:Method)
CO (1) CO6300939A2 (en:Method)
EC (1) ECSP10010415A (en:Method)
ES (1) ES2556353T3 (en:Method)
IL (1) IL207530A (en:Method)
MX (1) MX2010009268A (en:Method)
MY (1) MY152271A (en:Method)
NZ (1) NZ587504A (en:Method)
PE (1) PE20091491A1 (en:Method)
RU (1) RU2525389C2 (en:Method)
SG (1) SG188179A1 (en:Method)
TW (1) TWI398441B (en:Method)
WO (1) WO2009105500A1 (en:Method)
ZA (2) ZA201005909B (en:Method)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
KR20080103996A (ko) 2006-02-16 2008-11-28 쉐링 코포레이션 Ｅｒｋ 억제제로서 피롤리딘 유도체
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
WO2010021978A2 (en) * 2008-08-19 2010-02-25 Schering Corporation Il-8 biomarker
EP2448942B1 (en) 2009-07-02 2014-09-24 Merck Sharp & Dohme Corp. FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS
WO2011041152A1 (en) 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors
US8999957B2 (en) * 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2630133A1 (de) 2010-10-22 2013-08-28 Bayer Intellectual Property GmbH Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
JP2014500874A (ja) * 2010-11-16 2014-01-16 メディミューン，エルエルシー 抗ｉｇｆ抗体を用いた治療レジメン
WO2013015918A1 (en) 2011-07-22 2013-01-31 Iowa State University Research Foundation, Inc. Method of regioselective synthesis of substituted benzoates
MX354675B (es) 2012-03-01 2018-03-15 Array Biopharma Inc Inhibidores de serina/treonina cinasa.
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
KR102057877B1 (ko) * 2012-07-18 2019-12-20 노스 앤드 사우스 브라더 파마시 인베스트먼트 컴파니 리미티드 질소함유 헤테로고리 유도체 및 그의 약물에서의 용도
BR112015006990A2 (pt) * 2012-09-28 2017-07-04 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de pelo menos um composto
US9226922B2 (en) 2012-09-28 2016-01-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
AR095365A1 (es) * 2013-03-13 2015-10-14 Hoffmann La Roche Procedimiento para preparar compuestos benzoxazepina
US8871966B2 (en) 2013-03-15 2014-10-28 Iowa State University Research Foundation, Inc. Regiospecific synthesis of terephthalates
JP6427197B2 (ja) 2013-10-03 2018-11-21 クラ オンコロジー， インコーポレイテッド Ｅｒｋの阻害剤および使用方法
US10428387B2 (en) 2014-05-16 2019-10-01 University Of Massachusetts Treating chronic myelogenous leukemia (CML)
WO2016025639A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a chemotherapeutic agent and related methods
WO2016095089A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095088A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
AU2015362844B2 (en) * 2014-12-18 2019-10-24 Merck Sharp & Dohme Corp. (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
MX2017008078A (es) * 2014-12-19 2017-09-28 Merck Sharp & Dohme Composiciones de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h-indazol-5- il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il)fenil)-3,6-dihidrop iridin-1(2h)-il)-2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida para preparaciones farmaceuticas.
JP6737533B2 (ja) * 2015-04-03 2020-08-12 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー スピロ環式化合物
WO2017040362A1 (en) * 2015-09-03 2017-03-09 Merck Sharp & Dohme Corp. Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
CN109020789B (zh) * 2017-06-12 2021-08-13 浙江医药股份有限公司新昌制药厂 一种制备2-甲氧基丙烯的方法
WO2021067266A1 (en) * 2019-10-01 2021-04-08 Recurium Ip Holdings, Llc Pyrrolidinyl-based compounds
PH12022550874A1 (en) 2019-10-09 2023-03-27 Bayer Ag Novel heteroaryl-triazole compounds as pesticides
CA3160899C (en) 2019-12-06 2024-04-16 Medshine Discovery Inc. Spiro compound serving as erk inhibitor, and application thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
AU3215197A (en) 1996-05-30 1998-01-05 Merck & Co., Inc. A method of treating cancer
GB2323845A (en) 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
DE69841434D1 (de) 1997-07-18 2010-02-25 Novo Nordisk Healthcare Ag VERWENDUNG VON FVIIa ODER FVIIAi ZUR BEHANDLUNG VON ENDOTHELIALER FEHLFUNKTION BZW ZUR INHIBIERUNG DER ANGIOGENESE
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
SK14082001A3 (sk) 2000-02-05 2002-03-05 Vertex Pharmaceuticals Incorporated Deriváty pyrazolu ako inhibítory ERK a farmaceutická kompozícia, ktorá ich obsahuje
CA2369502A1 (en) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of erk
CA2403017A1 (en) 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
KR20030032035A (ko) 2000-09-15 2003-04-23 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물
AU2001290940A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
DE60125980T2 (de) * 2000-11-20 2007-10-25 Scios Inc., Sunnyvale P38kinase-inhibitoren vom piperidin/piperazin-typ
MXPA03005610A (es) 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
CA2440842A1 (en) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Novel 1h-indazole compounds
US6706711B2 (en) 2001-04-27 2004-03-16 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitor
MXPA03009846A (es) 2001-04-27 2004-05-05 Vertex Pharma Derivados de triazol inhibidores de cinasa y usos de los mismos.
MXPA04001087A (es) 2001-08-03 2004-07-08 Vertex Pharma Derivados de pirazol como inhibidores de cinasa y uso de los mismos.
ATE491701T1 (de) 2001-08-03 2011-01-15 Vertex Pharma Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
AU2002359291C1 (en) 2001-10-23 2008-11-20 Merck Serono Sa Azole derivatives and pharmaceutical compositions containing them
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1506189A1 (en) 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
AU2003233605A1 (en) 2002-05-24 2003-12-12 The University Of Utah Research Foundation Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
CN1656079A (zh) * 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP4845379B2 (ja) 2002-09-19 2011-12-28 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン
EP1606284B1 (en) 2003-03-13 2009-12-02 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
JP2007521331A (ja) * 2003-11-19 2007-08-02 シグナル ファーマシューティカルズ，エルエルシー 複数キナーゼの標的化による疾患及び障害の治療方法
CA2548951A1 (en) 2003-12-22 2005-07-14 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
WO2005100342A1 (en) 2004-03-26 2005-10-27 Vertex Pharmaceuticals, Incorporated Pyridine inhibitors of erk2 and uses thereof
EP1756082A1 (en) 2004-04-13 2007-02-28 Astex Therapeutics Limited 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators
ES2751761T3 (es) 2004-05-14 2020-04-01 Vertex Pharma Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
JP4993604B2 (ja) 2004-05-14 2012-08-08 バーテックス ファーマシューティカルズ インコーポレイテッド ピロリルピリミジンｅｒｋプロテインキナーゼインヒビターのプロドラッグ
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
JP2008525461A (ja) 2004-12-23 2008-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ｅｒｋプロテインキナーゼの選択的阻害剤およびその使用
CN100377868C (zh) * 2005-03-24 2008-04-02 中国科学院物理研究所 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
US8217042B2 (en) * 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
PL1966151T3 (pl) * 2005-12-13 2012-02-29 Merck Sharp & Dohme Policykliczne pochodne indazoli jako inhibitory ERK
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
KR20080103996A (ko) 2006-02-16 2008-11-28 쉐링 코포레이션 Ｅｒｋ 억제제로서 피롤리딘 유도체
WO2007123186A1 (ja) * 2006-04-20 2007-11-01 Takeda Pharmaceutical Company Limited 医薬
US7601852B2 (en) * 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
AU2007269836A1 (en) * 2006-06-30 2008-01-10 Albany Molecular Research, Inc. Substituted piperidines that increase P53 activity and the uses thereof
US7671832B2 (en) * 2006-07-10 2010-03-02 Philips Lumileds Lighting Company, Llc Multi-colored LED backlight with color-compensated clusters near edge
CA2681756C (en) 2007-03-28 2015-02-24 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
PE20090326A1 (es) * 2007-06-05 2009-04-04 Schering Corp Compuestos heterociclos como inhibidores de erk
CN101790526A (zh) 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
US20110038876A1 (en) 2007-06-18 2011-02-17 Robert Sun Heterocyclic compounds and use thereof as erk inhibitors
WO2011041152A1 (en) 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors

Also Published As

Publication number Publication date
BRPI0908120A8 (pt) 2017-10-24
NZ587504A (en) 2012-09-28
RU2010138635A (ru) 2012-03-27
JP5276676B2 (ja) 2013-08-28
MX2010009268A (es) 2010-09-14
TWI398441B (zh) 2013-06-11
CO6300939A2 (es) 2011-07-21
US8716483B2 (en) 2014-05-06
CA2714479A1 (en) 2009-08-27
IL207530A0 (en) 2010-12-30
AR070460A1 (es) 2010-04-07
CL2009000394A1 (es) 2011-02-11
AU2009215534B2 (en) 2014-06-26
JP2011513225A (ja) 2011-04-28
BRPI0908120A2 (en:Method) 2017-08-22
ZA201005909B (en) 2014-03-26
CN102015693A (zh) 2011-04-13
MY152271A (en) 2014-09-15
CN102015693B (zh) 2014-10-29
EP2260031B1 (en) 2015-10-07
TW200948799A (en) 2009-12-01
ES2556353T3 (es) 2016-01-15
AU2009215534B8 (en) 2014-07-10
RU2525389C2 (ru) 2014-08-10
ZA201400396B (en) 2014-12-23
WO2009105500A1 (en) 2009-08-27
AU2009215534A1 (en) 2009-08-27
ES2556353T8 (es) 2017-10-13
US20110189192A1 (en) 2011-08-04
ECSP10010415A (es) 2010-09-30
PE20091491A1 (es) 2009-09-25
AU2009215534A2 (en) 2010-12-23
SG188179A1 (en) 2013-03-28
EP2260031A1 (en) 2010-12-15
AU2009215534A8 (en) 2014-07-10
KR20100117123A (ko) 2010-11-02

Similar Documents

Publication Publication Date Title
IL207530A (en) Triazolyl-phenyl compounds and their use in the manufacture of a cancer treatment drug
AU2017232516B2 (en) Substituted inhibitors of menin-MLL and methods of use
KR102419524B1 (ko) 메닌-mll의 가교된 이환식 억제제 및 사용 방법
EP3205650B1 (en) Egfr inhibitor, and preparation and application thereof
Krystal et al. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells
EP2694515B1 (en) Protein kinase inhibitors
RU2008128119A (ru) Новые соединения, действующие как ингибиторы erk
RU2009148867A (ru) Полициклические производные индазола и их применение в качестве ингибиторов erk для лечения рака
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
JP2017533266A5 (en:Method)
NZ596487A (en) 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES AND THE USE THEREOF AS PI3K INHIBITORS
CN116217581A (zh) 用于抑制多发性内分泌抑癌蛋白与mll蛋白质的相互作用的方法及组合物
RU2018134981A (ru) Конъюгаты, содержащие ингибиторы RIPK2
CN114599361A (zh) Prmt5抑制剂的药物组合物
IL274936B2 (en) Transmuted heterocyclic bicyclic compounds as prmt5 inhibitors
JP2011506402A5 (en:Method)
JP2010538091A5 (en:Method)
KR20150104089A (ko) 치환된 인돌-5-올 유도체와 그들의 치료적 용도
AU2019316858B2 (en) Smad3 inhibitors
Batran et al. Design, synthesis, and molecular modeling of quinoline‐based derivatives as anti‐breast cancer agents targeting EGFR/AKT signaling pathway
JPWO2020032105A5 (en:Method)
RU2013120357A (ru) Фармацевтические комбинации
JP2019537598A (ja) ２−多置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途
CA3136492A1 (en) Heterocyclic compounds and uses thereof
Husseiny et al. Aminopyridone-linked benzimidazoles: a fragment-based drug design for the development of CDK9 inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed